Search Results 51-60 of 16484 for ������������KA���:ZA31���24������ ���������������������������������

  1. A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma - Mayo Clinic

    ... 24 months) other than the disease being treated under study. The only allowed exceptions are: a) non-muscle invasive bladder cancer treated within the last 24 ...

  2. Oncology (Medical) - Clinical trials - Mayo Clinic

    Mayo Clinic Oncology — Medical oncologists at Mayo Clinic offer innovative treatments for cancers of the organs, bones, muscles and connective tissues.

  3. Publications - Cady K. Block, Ph.D., ABPP-CN, L.P. - Mayo Clinic

    2024 Oct 21; 1-24 [Epub ahead of print] View ... 2024 Jun; 155:109669 Epub 2024 Apr 24. View PubMed ... KA, Del Bene VA. Diverse experiences and ...

  4. Surgical Drain Fluid for Detection of Molecular Residual Disease for HPV(-) Head and Neck Cancers - Mayo Clinic

    ... 24- months post-surgery in patients with HPV(-) head and neck cancer. Participation eligibility. Participant eligibility includes age, gender, type and stage ...

  5. IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma - Mayo Clinic

    Rochester, Minnesota: 24-000858. NCT ID: NCT05987332. Sponsor Protocol Number: IDE196-002. About this study. The purpose of this study is to compare IDE196 + ...

  6. Drugs and Supplements - Mayo Clinic

    Look up information about prescription drugs, over-the-counter medications, herbs, vitamins and supplements.

  7. Clinical trials - Oncology (Medical)

    Rochester, Minn. This is a survey study to describe how women with Lynch syndrome are being screened for gynecologic cancer risk, their perception of cancer ...

  8. A Study of the Clinical Experience and Acceptance of the Artificial Pancreas

    ... 24/7 in-home usability prior to initiating a large randomized controlled trial. Participation eligibility. Participant eligibility includes age, gender, type ...

  9. ... 24 hrs (6 yrs) 52 mg intrauterine device,959.24 392,636000003,50419042401,levonorgestreL 17.5 mcg/24 hrs (5yrs) 19.5mg intrauterine device,"1,907.02" 415 ...

  10. Publications - Tasneem Z. Naqvi, M.B.B.S., M.D. - Mayo Clinic

    Zeineddine RM, Naqvi TZ, Farina JM, Shawwaf KA, D'Cunha J, Jaroszewski DE. ... 2015 Dec; 210: (6)1118-24; discussion 1124-5. ... Epub 2012 Jan 24. View ...